PLUN Stock Overview
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ProstaLund AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.97 |
| 52 Week High | kr4.01 |
| 52 Week Low | kr0.91 |
| Beta | 0.79 |
| 1 Month Change | -16.55% |
| 3 Month Change | -43.39% |
| 1 Year Change | -74.12% |
| 3 Year Change | -83.19% |
| 5 Year Change | n/a |
| Change since IPO | -93.95% |
Recent News & Updates
Shareholder Returns
| PLUN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -1.6% | 3.3% | -0.7% |
| 1Y | -74.1% | -61.4% | 4.4% |
Return vs Industry: PLUN underperformed the Swedish Medical Equipment industry which returned -7.5% over the past year.
Return vs Market: PLUN underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| PLUN volatility | |
|---|---|
| PLUN Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: PLUN's share price has been volatile over the past 3 months.
Volatility Over Time: PLUN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 7 | Johan Wennerholm | prostalund.se |
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow soft stent; Oruflow, a urine flow meter; Dosi-Fuser, a disposable continuous infusion system; and Dosi-Flow, a gravitation unit with a flow regulator for dosing of medicines. The company also provides Schelin Catheter, an injection tool that allows the urologists to administer drugs into the prostate in a sterile way through the urethra.
ProstaLund AB (publ) Fundamentals Summary
| PLUN fundamental statistics | |
|---|---|
| Market cap | kr74.14m |
| Earnings (TTM) | -kr17.01m |
| Revenue (TTM) | kr22.21m |
3.3x
P/S Ratio-4.4x
P/E RatioIs PLUN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUN income statement (TTM) | |
|---|---|
| Revenue | kr22.21m |
| Cost of Revenue | kr6.55m |
| Gross Profit | kr15.65m |
| Other Expenses | kr32.66m |
| Earnings | -kr17.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 70.49% |
| Net Profit Margin | -76.60% |
| Debt/Equity Ratio | 2.4% |
How did PLUN perform over the long term?
See historical performance and comparison